The 44th Annual Meeting of ESPID, running June 1-5, 2026 in Bologna, Italy, is not simply a calendar fixture for paediatric infectious disease professionals. It is the primary gathering where the European paediatric ID community sets its research agenda, evaluates new diagnostics and vaccines, and builds the clinical relationships that shape how children are treated for infectious diseases across the continent and beyond. At its 44th edition, this meeting carries the weight of institutional authority that few other events in this niche can match.
You can also follow coverage and logistics for ESPID 2026 on TradeShowIntel.
Why Paediatric Infectious Disease Makes ESPID 2026 Urgent
Paediatric infectious diseases occupy a uniquely pressured corner of medicine. Children are not small adults, and the pharmacological, immunological, and epidemiological considerations that govern their care require dedicated expertise. Several dynamics make the timing of ESPID 2026 particularly consequential:
These are not abstract research concerns. They translate directly into procurement decisions for diagnostics, formulary reviews for hospitals, and strategic pivots for pharmaceutical and vaccine developers. Bologna in June is where those conversations get structured.
The Concentration of Expertise That Defines ESPID 2026
The core argument for attending ESPID 2026 is density. The meeting draws paediatric infectious disease specialists, clinicians, researchers, public health professionals, and allied health workers from across Europe and internationally into a single venue over five days. That concentration does not happen at regional meetings, institutional conferences, or through any digital channel.
For pharmaceutical companies and vaccine developers, this is the room where the clinicians who prescribe, recommend, and evaluate their products are gathered at scale. A medical affairs team that works the ESPID floor has access to the decision-making layer of paediatric ID in a way that months of individual outreach cannot replicate. The exhibitor profile at this meeting spans diagnostics manufacturers, medical equipment suppliers, healthcare IT providers, and research institutions, meaning the competitive landscape is visible and benchmarkable in a single afternoon.
For clinicians and researchers, the value runs in the opposite direction. Expert-led sessions, workshops, and debates compress months of literature review into structured, peer-reviewed formats. More importantly, the informal conversations between sessions, the hallway exchanges after a workshop, and the introductions made at the exhibition floor are where collaborative research projects and clinical trial partnerships actually begin. No grant application captures the moment a researcher from Copenhagen connects with a clinician from Athens over a shared patient population problem.
For diagnostics manufacturers in particular, ESPID represents a rare opportunity to get direct clinical feedback on products from the specialists who use them in the most demanding paediatric settings. That feedback loop, compressed into five days, is operationally irreplaceable.
What Actually Gets Decided at ESPID 2026 in Bologna
The downstream consequences of ESPID 2026 are concrete. This is where vendor shortlists for diagnostic platforms get shaped, often informally, as procurement-influencing clinicians compare notes on what they have seen in the exhibition hall and what peers in other countries are using. A diagnostics company that is absent from the floor is absent from that conversation.
For vaccine developers, ESPID is where clinical advisory relationships get initiated. The researchers presenting data in Bologna are often the same individuals who sit on hospital formulary committees, contribute to national immunisation advisory bodies, or lead the multi-centre trials that generate the evidence base for regulatory submissions. Meeting them here, in context, is categorically different from a cold introduction.
Public health professionals attending ESPID 2026 leave with updated surveillance intelligence from peers across multiple European countries, which directly informs outbreak preparedness planning and resource allocation back home. That intelligence is not published in journals for months after the meeting.
For medical students and fellows, the calculus is different but equally real. Presenting work at ESPID, connecting with senior researchers, and being seen in this community at an early career stage has measurable effects on fellowship placements and research collaborations that follow for years.
With five days of programming, the Habsy App gives exhibitors a practical way to capture the substance of each conversation on the floor, not just the contact card. Scanning a badge, adding a 15-second voice note about what a clinician said about their current diagnostic workflow, and tagging their buying timeline means your follow-up after Bologna is built on actual context, not a stack of cards you can no longer place.
The Cost of Absence from ESPID 2026
For pharmaceutical and diagnostics companies not present in Bologna, the practical consequence is straightforward: competitors who are there will be building the clinical relationships and advisory connections that shape product positioning for the next 12-18 months. For clinicians and researchers who skip the meeting, the cost is slower access to emerging data and weaker positioning within the collaborative networks that drive funded research. In a field as specialised as paediatric infectious diseases, the ESPID community is small enough that absence is noticed and large enough that the conversations happening without you carry real weight.
Prefer TradeShowIntel in your Google results
Add us as a preferred source and our event coverage shows up higher when you search on Google.
Add us as a preferred source on Google